Teri,
The following article from 6/2006 on the Medscape website indicates that the two regimens are pretty comparable in outcome. (I tried to do it as an attachment, but that was over my head!)
NEW YORK (Reuters Health) Jun 16 - A combination of irinotecan and cisplatin (IP) appears to be as effective as etoposide and cisplatin (EP) in patients with previously untreated extensive small-cell lung cancer, according to US and Australian researchers.
"The IP regimen, in the dose and schedule given in our study," lead investigator Dr. Nasser Hanna told Reuters Health, "demonstrated comparable activity to the EP regimen in terms of response rate, time to disease progression, and overall survival. Those in the IP arm had less neutropenia and neutropenic fever, but higher rates of diarrhea, nausea and vomiting."
In the May 1st issue of the Journal of Clinical Oncology, Dr. Hanna of Indiana University, Indianapolis and colleagues report on their study involving 221 patients who were randomized to IP and 110 who were randomized to receive EP.
Side effects included neutropenia in 36.2% of IP patients versus 86.5% of those given EP. However, 21.3% of the IP patients had diarrhea versus none of the EP group.
There was no significant difference in overall response (48% versus 43.6%), median time to progression or overall survival.
Thus concluded Dr. Hanna, "either regimen should be considered an acceptable standard treatment for patients with extensive stage small cell lung cancer."
In an accompanying editorial, Dr. Michael C. Perry of the University of Missouri, Columbia, agrees, noting that although there was greater hematologic toxicity with ER there was more gastrointestinal toxicity with IR. Other responses were similar.